To appraise the clinical and cost effectiveness of mepolizumab within its marketing authorisation for treating chronic obstructive pulmonary disease.
Status Awaiting development
Decision None selected
Process STA pre-2018
ID number 1237

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
13 December 2018 Following on from advice received from the company the timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.
20 September 2017 - 18 October 2017 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual